// App-Quantinova.ai

5031 : Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.

Researchers

Presenter

  • Scott T. Tagawa

Principal Investigators

  • Emmanuel S. Antonarakis

  • Marie Vanhuyse

  • Shalu Suri

  • Timothy B Lannin

  • Conor Gruber

  • Erica Pratt

  • Guru Sonpavde

  • Mario A. Eisenberger

  • David M. Nanus

  • Daniel Worroll

  • Luigi Portella

  • Brian J. Kirby

  • John Stewart

  • Atef Zaher

  • Fred Saad

  • Paraskevi Giannakakou

  • Shinsuke Tasaki

  • Ada Gjyrezi

Medical Centers

  • Cornell University, Ithaca, NY

  • Weill Medical College of Cornell University, New York, NYMedical Oncology, Montreal General Hospital, Montreal, QC, CanadaThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Sanofi, Laval, QC, Canada

  • University of Montreal, Montreal, QC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Cabazitaxel

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved